Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Income: 2017-2025

Historic Net Income for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$36.6 million.

  • Dianthus Therapeutics' Net Income fell 43.90% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 87.03%. This contributed to the annual value of -$84.5 million for FY2024, which is 94.65% down from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Net Income is -$36.6 million, which was down 16.20% from -$31.5 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Net Income high stood at -$7.1 million for Q1 2023, and its period low was -$36.6 million during Q3 2025.
  • For the 3-year period, Dianthus Therapeutics' Net Income averaged around -$20.5 million, with its median value being -$17.5 million (2024).
  • Data for Dianthus Therapeutics' Net Income shows a maximum YoY plummeted of 165.66% (in 2024) over the last 5 years.
  • Over the past 4 years, Dianthus Therapeutics' Net Income (Quarterly) stood at -$10.1 million in 2022, then fell by 4.57% to -$10.5 million in 2023, then plummeted by 165.66% to -$27.9 million in 2024, then plummeted by 43.90% to -$36.6 million in 2025.
  • Its Net Income stands at -$36.6 million for Q3 2025, versus -$31.5 million for Q2 2025 and -$29.4 million for Q1 2025.